The adeno-associated viral vector market is anticipated to grow at a CAGR of more than 10% by 2035, claims Roots Analysis 

Published: March 2023

Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections 

Roots Analysis has announced the addition of “Adeno-Associated Viral Vector Market, 2022-2035” report to its list of offerings. 

Owing to their unique biology, simple structure and lack of disease correlation, the adeno-associated viral vectors have garnered significant interest within the medical community. In fact, various adeno-associated viral vector-based therapies have been developed for the treatment of multiple indications, including retinitis pigmentosa, cystic fibrosis and Duchenne muscular dystrophy. As a result, the demand for such vectors have increased tremendously, thereby creating lucrative opportunities for the players engaged in the adeno-associated viral vector market.

To order this 250+ page report, which features 150+ figures and 225+ tables, please visit link

Key Market Insights

More than 550 adeno-associated viral vector-based therapies have been / are being evaluated across different stages of development for the treatment of various disorders
Close to 20% of the pipeline candidates are under clinical evaluation; majority (26%) of these candidates are being developed for the treatment of neurological disorders, followed by those being evaluated for the treatment of ophthalmic disorders (21%).

80+ industry stakeholders claim to have the required capability to manufacture adeno-associated viral vectors
The market is currently dominated by the presence of various mid-sized industry players (53%); of these 65% of the players possess in-house manufacturing capabilities, whereas 44% of players are contract manufacturers.

Over 30 players are involved in the development of adeno-associated viral vector platforms
More than 90% of these players offer their technologies for gene therapy, followed by those offering platforms for cell therapy (23%). It is worth mentioning that two technologies can manufacture vectors at all scales of operation, including preclinical, clinical and laboratory.

More than 155 clinical trials have been registered for the evaluation of adeno-associated viral vector-based therapies, worldwide 
The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 20%, since 2010. Of the total number of trials registered, close to 25% have already been completed, while 46% of the studies are actively recruiting participants.

Partnership activity within this domain has increased at a CAGR of ~50%, between 2017 and 2021 
More than 60% of the reported deals were established since 2020, with the maximum activity (~50%) being reported in 2021. Majority of the partnerships were established for product development (30%), followed by agreements inked for research and development (15%).

Over 4,370 patents have been filed / granted related to adeno-associated viral vectors, since 2017 
Close to 35% of these patents were filed / granted in North America, followed by Asia-Pacific (32%). It is worth highlighting that, in addition to the industry players, various non-industry / academic players have also filed patents related to adeno-associated viral vectors; these include University of Pennsylvania, University of Florida and the Research Institute of Nationwide Children's Hospital.

More than 50 start-ups have emerged in the last 10 years in the adeno-associated viral vector domain 
Close to 60% of the start-ups have been established in North America. Among these, more than 95% of the firms are based in the US. This is followed by Europe, accounting for more than 30% of the start-ups focused on adeno-associated viral vectors.

North America is anticipated to capture larger share of the adeno-associated viral vector market by 2035
The market will be primarily driven by the manufacturers developing therapies for the treatment of oncological disorders (20%). In addition, by 2035, majority market share of the adeno-associated viral vector-based therapies is anticipated to be dominated by commercial scale of operation (46%), followed by preclinical (40%) and clinical (14%).

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered
  • Which adeno-associated viral vector-based therapy candidates are being developed across early and late stages of development? Which disease indications are targeted by such therapies?
  • Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of adeno-associated viral vectors?
  • Which type of adeno-associated viral vector related technologies are presently offered / being developed by the industry players?
  • Which geographies are the most active in conducting clinical trials related to adeno-associated viral vectors?
  • Which partnership models are commonly adopted by industry and non-industry stakeholders?
  • Which companies are likely to partner with adeno-associated viral vector and gene therapy product manufacturers?
  • What are the different initiatives recently undertaken by the start-ups engaged in the development of adeno-associated viral vectors?
  • Which factors are likely to influence the decision of adeno-associated viral vector therapy developers for outsourcing manufacturing operations? 
  • How is the current and future market opportunity related to adeno-associated viral vectors likely to be distributed across key market segments?

The financial opportunity within the adeno-associated viral vector market has been analysed across the following segments:

  • Type of Therapy
    • Gene Augmentation
    • Immunotherapy
    • Other Therapies
  • Type of Gene Delivery Method Used
    • Ex vivo
    • In vivo 
  • Target Therapeutic Area
    • Genetic Disorders
    • Hematological Disorders
    • Infectious Diseases
    • Metabolic Disorders
    • Ophthalmic Disorders
    • Muscle Disorders
    • Neurological Disorders
    • Others
  • Scale of Operation
    • Preclinical
    • Clinical
    • Commercial
  • Application Area
    • Gene Therapy
    • Cell Therapy
    • Vaccines
  • Geographical Regions 
    • North America
    • Europe
    • Asia-Pacific 
    • MENA
    • Latin America
    • Rest of the World

The research also includes detailed profiles of the key players (listed below) engaged in the adeno-associated viral vector market; each profile features an overview of the company, its financial information (if available), details related to its manufacturing facilities and proprietary vector manufacturing technology portfolio, and recent developments and an informed future outlook.

  • Abeona Therapeutics
  • Aldevron
  • Oxford BioMedica
  • Sanofi
  • WuXi AppTec
  • Yposkesi

The report features inputs from eminent industry stakeholders, according to whom, the anticipated increase in the demand for gene therapies, is the most prominent driver of the growth of the adeno-associated viral vector market. The report includes detailed transcripts of discussions held with following industry representatives:

For additional details, please visit or email 

You may also be interested in the following titles:

  1. Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market (5th Edition): Industry Trends and Global Forecast, 2022-2035
  2. Gene Therapy Market (5th Edition): Industry Trends and Global Forecast, 2022-2035
  3. Gene Therapies & Associated Vectors Market: Intellectual Property Landscape
  4. CART-T Cell Therapies: Intellectual Property Landscape

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry